期刊文献+

下调CDH17基因表达对顺铂耐药的人胃癌BGC823细胞凋亡与增殖的影响 被引量:3

Effect of Down-regulation of CDH17 Gene Expression on Apoptosis and Proliferation of Cisplatin-resistant Human Gastric Cancer BGC823 Cells
下载PDF
导出
摘要 目的探讨下调肝肠钙粘连蛋白(CDH17)基因对顺铂耐药的人胃癌BGC823细胞凋亡和增殖的影响。方法构建si CDH17慢病毒转染的顺铂耐药人胃癌细胞株BGC823,运用噻唑蓝(MTT)实验检测细胞活力、Hoechst33258染色法和流式Annexin V-FITC/PI检测法观察细胞凋亡情况,Western blotting检测增殖凋亡通路相关蛋白的表达水平变化。结果 MTT实验表明,下调CDH17能够显著降低人胃癌BGC823细胞的存活率(P<0.05),提高人胃癌BGC823细胞对顺铂的敏感性;Hoechst33258染色法观察和Annexin V/PI双染色实验表明,下调CDH17可促进BGC823耐药细胞凋亡;Western blotting实验显示下调CDH17能够增加Bax、Cyt-c以及Cyclin D1的表达并降低Bcl-2和Bcl-x L的表达,表明CDH17可通过影响线粒体凋亡途径参与调控人胃癌BGC823细胞对顺铂的耐药性。结论下调CDH17可通过调控线粒体途径促进顺铂耐药BGC823细胞的凋亡,并调控周期蛋白肝肠钙粘连蛋白的表达来抑制耐药细胞的增殖,最终达到下调CDH17提高人胃癌BGC823细胞对顺铂的敏感性的效果。 Objective To investigate the effect of down-regulation of CDH17 gene on apoptosis and proliferation of cisplatin-resistant human gastric cancer BGC823 cells.Methods The cisplatin-resistant human gastric cancer cell line BGC823 was transfected with siCDH17 lentivirus.Cell viability was measured by MTT assay.Hoechst33258 staining and Annexin V-FITC/PI staining were used to observe the apoptosis of cells.Western blotting was used to detect the expression of apoptosis-related proteins.Results MTT assay showed that CDH17 significantly reduced the survival rate of human gastric cancer BGC823 cells(P<0.05)and enhanced the sensitivity of human gastric cancer BGC823 cells to cisplatin.Hoechst33258 staining and Annexin V/PI double staining showed that down-regulation of CDH17 could promote the apoptosis of cisplatin-resistant BGC823 cells.Western blotting showed that down-regulation of CDH17 could increase the expressions of Bax,Cyt-c and CyclinD1 and decrease the expressions of Bcl-2 and Bcl-xL,indicating that CDH17 might be involved in the regulation of cisplatin-resistance in human gastric cancer BGC823 cells through mitochondrial apoptosis pathway.Conclusion Down-regulation of CDH17 can promote the apoptosis of cisplatin-resistant BGC823 cells by regulating the mitochondrial pathway and regulate the expression of cyclin-dependent protein to inhibit the proliferation of drug-resistant cells.Finally,down-regulation of CDH17 can enhance the sensitivity of human gastric cancer BGC823 cells to cisplatin.
作者 刘蒙 韩峥 朱庆曦 谭洁 田霞 LIU Meng;HAN Zheng;ZHU Qingxi;TAN Jie;TIAN Xia(Department of Gastroenterology,the third Hospital of Wuhan City,Wuhan 430060,China)
出处 《医药导报》 CAS 北大核心 2018年第4期416-421,共6页 Herald of Medicine
基金 湖北省自然科学基金资助项目(2013CFB358) 武汉市卫计委基金资助项目(WX14C18 WX15C09) 武汉市科技局应用基础研究计划项目(2015060101010064)
关键词 顺铂 肝肠钙粘连蛋白CDH17 细胞凋亡 耐药性 Cisplatin Liver-intestine cadherin CDH17 Apoptosis Chemoresistance
  • 相关文献

参考文献2

二级参考文献22

  • 1Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogene- sis. Am J Surg Pathol, 1983,7:507-519.
  • 2Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Patho1,2008,39 : 1411-1419.
  • 3Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs) :a review. Eur J Cancer, 2002, 38(Suppl 5) :S39-51.
  • 4Miettinen M, Lasota J. Gastrointestinal stromal tumors:review on mor- phology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med ,2006,130 : 1466-1478.
  • 5Fletcher CD, Berman JJ, Corless CL, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 2002, 33 : 459 - 465.
  • 6Gervaz P, Huber O, Morel P. Surgical management of gastrointestinal stronml tumours. Br J Surg,2009 ,96 :567-578.
  • 7Gold JS, Dematteo RP. Combined surgical and molecular therapy:the gastrointestinal stromal tumor model. Ann Surg,2006,244 : 176-184.
  • 8Cohen MH, Cortazar P, Justice R, et al. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oneo/ogist,2010,15:300-307.
  • 9Hassan I,You YN,Shyyan R, et al. Surgically managed gastrointestinal stromal tumors : a comparative and prognostic analysis. Ann Surg Oncol, 2008,15:52-59.
  • 10Rutkowski P, Debiec-Rychter M, Nawecki ZI, et al. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Med Sci Monit ,2007,13 : CR515-522.

共引文献26

同被引文献30

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部